Roche has named Mike Burgess as head of oncology discovery and translational area (DTA). Burgess joined Roche in 2006 having previously worked at Eli Lilly.
Robert Bradway has been promoted to the position of president and chief operating officer at Amgen. Bradway has worked at Amgen since 2006 when he joined from Morgan Stanley.
Delcath Systems has hired Peter Graham to fill the newly created position of executive vice president (EVP) and general counsel. Graham has previously worked at ACIST Medical Systems and E-Z-EM.
David Boyle II will work as interim president and CEO of AVI BioPharma while continuing in his current position of chief financial officer. Boyle joined AVI from Xoma in 2008.
InteKrin Therapeutics has appointed Roman Skowronski as VP, clinical development. Skowronski has previously worked at AcelRx, Alza and Alexza.
Joseph Cook has been elected to the board of directors at the Tennessee Biotech Association (TBA). Before joining TBA Cook held positions at Amylin Pharmaceuticals and Eli Lilly.
BioPhausia AB has named Niklas Prager as chairman of its board of directors. Prager is the current CEO of Qbtech AB and former CEO of Pfizer Sverige.
Michael Polito has joined Heritage Pharmaceuticals as chief financial officer. Polito was US controller of Barr Pharmaceuticals before the company was acquired by Teva.
Orexigen Therapeutics has appointed Wendy Dixon to its board of directors. Dixon has previously worked at Bristol-Myers Squibb, Merck & Co and SmithKline French.
William Ringo has been named as chairman of the board of directors at Sangamo BioSciences. Ringo will retire from his post at Pfizer at the end of April. He has also worked at Abgenix, InterMune and Eli Lilly.